Preparation, efficacy and comparison of costs for compounded preparation of 3,4-diaminopirydine on the treatment of lambert-eaton miastenic syndrome: about a case

被引：0

作者：

Medarde Caballero, Catalina ^{[1
]}

Ruiz Fuentes, Salvador ^{[1
]}

Belda Rustarazo, Susana ^{[1
]}

Fernandez Lopez, Cristina ^{[1
]}

Gomez Pena, Celia ^{[1
]}

Garcia Fernandez, Cristina ^{[1
]}

Gonzalez Garcia, Lorena ^{[1
]}

Moron Romero, Rocio ^{[1
]}

Gonzalez Medina, M. Carmen ^{[1
]}

机构：

[1] Hosp Univ San Cecilio, Granada, Spain

来源：

INTERNATIONAL JOURNAL OF CLINICAL PHARMACY | 2015年 / 37卷 / 01期

关键词：

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

DI013

引用

页码：262 / 263

页数：2

共 18 条

[1] 3,4-diaminopyridine for the treatment of Lambert-Eaton myasthenic syndrome
Wirtz, Paul W.
Titulaer, Maarten J.
van Gerven, Joop M. A.
Verschuuren, Jan J.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2010, 6 (06) : 867 - 874
[2] TREATMENT OF LAMBERT-EATON SYNDROME - 3,4-DIAMINOPYRIDINE AND PYRIDOSTIGMINE
LUNDH, H
NILSSON, O
ROSEN, I
NEUROLOGY, 1984, 34 (10) : 1324 - 1330
[3] 3,4-DIAMINOPYRIDINE IN THE TREATMENT OF LAMBERT-EATON MYASTHENIC SYNDROME
MCEVOY, KM
WINDEBANK, AJ
DAUBE, JR
LOW, PA
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (23): : 1567 - 1571
[4] 3,4-Diaminopyridine (amifampridine) for the treatment of Lambert-Eaton myasthenic syndrome
Lindquist, Sabine
Stangel, Martin
EXPERT OPINION ON ORPHAN DRUGS, 2014, 2 (03): : 293 - 300
[5] LAMBERT-EATON MYASTHENIC SYNDROME - RESPONSE TO TREATMENT WITH 3,4-DIAMINOPYRIDINE
MORATA, C
ALFARO, A
CHUMILLAS, MJ
MONTALAR, J
MEDICINA CLINICA, 1995, 104 (04): : 156 - 156
[6] Case Report: 3,4-Diaminopyridine for the Treatment of Lambert-Eaton Myasthenic Syndrome during Pregnancy
Ellfolk, Maria
Malm, Heli
BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY, 2014, 100 (07) : 535 - 536
[7] 3,4-diaminopyridine (DAP) in the treatment of Lambert-Eaton myasthenic syndrome (LEMS)
Sanders, DB
MYASTHENIA GRAVIS AND RELATED DISEASES: DISORDERS OF THE NEUROMUSCULAR JUNCTION, 1998, 841 : 811 - 816
[8] PRACTICAL ASPECTS OF 3,4-DIAMINOPYRIDINE TREATMENT OF THE LAMBERT-EATON MYASTHENIC SYNDROME
LUNDH, H
NILSSON, O
ROSEN, I
JOHANSSON, S
ACTA NEUROLOGICA SCANDINAVICA, 1993, 88 (02): : 136 - 140
[9] ORAL 3,4-DIAMINOPYRIDINE IN THE TREATMENT OF THE LAMBERT-EATON MYASTHENIC SYNDROME (LEMS)
MURRAY, NMF
NEWSOMDAVIS, J
KARNI, Y
WILES, CM
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1984, 47 (09): : 1052 - 1053
[10] LONG-TERM TREATMENT OF LAMBERT-EATON SYNDROME WITH 3,4 DIAMINOPYRIDINE
JOST, WH
MIELKE, U
FORRETTKAMINSKY, MC
SCHIMRIGK, K
REVUE NEUROLOGIQUE, 1992, 148 (12) : 776 - 779

← 1 2 →